Academy Award honorees, Disney legends, and pioneering storytellers-including Euzhan Palcy, John Canemaker, John Musker, Sandi DuBowski, and more-bring their acclaimed works and rare insights to Columbus audiences.
Read More
8849 is excited to introduce the latest addition to its lineup - TANK 4. Packed with cutting-edge features, the phone is set to redefine what a rugged phone can do. The 8849 Unihertz TANK 4 launches on Aliexpress this August 18. Don't miss the opportunity to own the ultimate rugged smartphone.
Read More
Exclusive Letter of Intent for West Coast distribution of Nimbus Boats USA
Expands Nautical Ventures' lineup with premium Scandinavian‑designed models
Strategic step to broaden Vision Marine's portfolio after acquiring Nautical Ventures
Enhances choice and experience for boaters in Florida's top market
Revenue for the Six Months Ended June 30, 2025 Increased 25%
Income from Operations for the Six Months Ended June 30, 2025 Increased 202%
Net Income for the Six Months Ended June 30, 2025 Increased 168%
The Company currently holds 170,687 common shares in Treasury from its Repurchase Program
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million
Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar
REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register
Read MoreCompany Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13
Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement
TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury
Stockholders' Equity Was $16.3 Million at Quarter End
2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated
Read More2Q25 Revenue growth to $21.2 million; Gross margin improves to 47.4% from 37.3% in 2Q24
2Q25 GAAP diluted EPS of $0.96 compared with $0.47 in 2Q24
2Q25 non-GAAP diluted adjusted EPS1of $1.30 compared with $0.55 in 2Q24
Raising full year 2025 GAAP EPS target to $3.15 per diluted share from $2.40 per diluted share
Raising full year 2025 non-GAAP adjusted EPS1 target to $3.80 per diluted share from $2.80 per diluted share
Announced $12.9 million in purchase orders from the USDA Forest Service subsequent to the quarter
Second Quarter Highlights
Per Class B share(3): $1.22 adjusted basic earnings up 8.0%; $1.21 basic earnings down 22.4%; 2024 included $0.44 revaluation gain in basic earnings
Sales increased 4.8% on 2.0% organic growth, 1.0% acquisition growth and 1.8% positive currency translation
Operating income(1) improved 6.1%, with a 16.6% operating margin(1) up 20 bps
Returned $155.8 million to shareholders: $55.8 million in dividends and repurchased 1.3 million Class B shares for $100.0 million
Six-Month Highlights
Per Class B share(3): $2.40 adjusted basic earnings up 8.6%; $2.39 basic earnings down 9.5%; 2024 included $0.44 revaluation gain in basic earnings
Sales increased 6.7% on 2.9% organic growth, 1.2% acquisition growth and 2.6% positive currency translation
Operating income(1) improved 9.1%, with a 16.7% operating margin(1) up 40 bps
Returned $312.1 million to shareholders: $112.1 million in dividends and repurchased 2.6 million Class B shares for $200.0 million
- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-
- Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 -
Read MoreInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval
Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program
Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Read MoreAgreement reached to acquire site in the Gujarat state in India with strategic access to textile waste for feedstock, renewable clean energy, industrial infrastructure.
Sufficient land on site for both initial 70,000 metric ton facility and further 100,000 metric ton capacity expansion.
Total cost of the land is $10.5M which represents $5M reduction in the amount included in project cost estimate.
1H 2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships
AI Nose 90-Day Roadmap to Power 2H 2025, with First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing
Read More
Revenue increased 67% y/y to $17.1M with Positive Adjusted EBITDA1 for Ninth Consecutive Quarter
Adjusted EBITDA1 increased 387% y/y to $2.9M or 17% of revenue
Net Profit for the quarter of $0.9M and EPS of $0.02
Reaffirms Fiscal 2025 Revenue Guidance Exceeding $60M, Driven by Strong Order Pipeline
Read MoreNet Revenue Outlook for 2025 Increased from $4.2 Million+ to $6.3 Million+, Representing Growth of 102%+, Based on Recent Transformative Merger with Gummy USA
Read More